|
1
|
Postma DS and Timens W: Remodeling in
asthma and chronic obstructive pulmonary disease. Proc Am Thorac
Soc. 3:434–439. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ding NH, Li JJ and Sun LQ: Molecular
mechanisms and treatment of radiation-induced lung fibrosis. Curr
Drug Targets. 14:1347–1356. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ramirez AM, Shen Z, Ritzenthaler JD and
Roman J: Myofibroblast transdifferentiation in obliterative
bronchiolitis: Tgf-beta signaling through smad3-dependent and
-independent pathways. Am J Transplant. 6:2080–2088. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wilson MS and Wynn TA: Pulmonary fibrosis:
Pathogenesis, etiology and regulation. Mucosal Immunol. 2:103–121.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Noble PW, Barkauskas CE and Jiang D:
Pulmonary fibrosis: Patterns and perpetrators. J Clin Invest.
122:2756–2762. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maharaj S, Shimbori C and Kolb M:
Fibrocytes in pulmonary fibrosis: A brief synopsis. Eur Respir Rev.
22:552–557. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sivakumar P, Ntolios P, Jenkins G and
Laurent G: Into the matrix: Targeting fibroblasts in pulmonary
fibrosis. Curr Opin Pulm Med. 18:462–469. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Phan SH: The myofibroblast in pulmonary
fibrosis. Chest. 122 Suppl 6:S286–S289. 2002. View Article : Google Scholar
|
|
9
|
Serhan CN: Pro-resolving lipid mediators
are leads for resolution physiology. Nature. 510:92–101. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Serhan CN and Chiang N: Resolution phase
lipid mediators of inflammation: Agonists of resolution. Curr Opin
Pharmacol. 13:632–640. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dalli J, Zhu M, Vlasenko NA, Deng B,
Haeggström JZ, Petasis NA and Serhan CN: The novel
13S,14S-epoxy-maresin is converted by human macrophages to maresin
1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts
macrophage phenotype. FASEB J. 27:2573–2583. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Marcon R, Bento AF, Dutra RC, Bicca MA,
Leite DF and Calixto JB: Maresin 1, a proresolving lipid mediator
derived from omega-3 polyunsaturated fatty acids, exerts protective
actions in murine models of colitis. J Immunol. 191:4288–4298.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nordgren TM, Heires AJ, Wyatt TA, Poole
JA, LeVan TD, Cerutis DR and Romberger DJ: Maresin-1 reduces the
pro-inflammatory response of bronchial epithelial cells to organic
dust. Respir Res. 14:512013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gong J, Wu ZY, Qi H, Chen L, Li HB, Li B,
Yao CY, Wang YX, Wu J, Yuan SY, et al: Maresin 1 mitigates
LPS-induced acute lung injury in mice. Br J Pharmacol.
171:3539–3550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li R, Wang Y, Zhao E, Wu K, Li W, Shi L,
Wang D, Xie G, Yin Y, Deng M, et al: Maresin 1, a proresolving
lipid mediator, mitigates carbon tetrachloride-induced liver injury
in mice. Oxid Med Cell Longev. 2016:92037162016.PubMed/NCBI
|
|
16
|
Akagi D, Chen M, Toy R, Chatterjee A and
Conte MS: Systemic delivery of proresolving lipid mediators
resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice.
FASEB J. 29:2504–2513. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Li R, Chen L, Tan W, Sun Z, Xia H,
Li B, Yu Y, Gong J, Tang M, et al: Maresin 1 inhibits
epithelial-to-mesenchymal transition in vitro and attenuates
bleomycin induced lung fibrosis in vivo. Shock. 44:496–502. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hinz B, Phan SH, Thannickal VJ, Galli A,
Bochaton-Piallat ML and Gabbiani G: The myofibroblast: One
function, multiple origins. Am J Pathol. 170:1807–1816. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Santana A, Saxena B, Noble NA, Gold LI and
Marshall BC: Increased expression of transforming growth factor
beta isoforms (beta 1, beta 2, beta 3) in bleomycin-induced
pulmonary fibrosis. Am J Respir Cell Mol Biol. 13:34–44. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang S, Cui H, Xie N, Icyuz M, Banerjee S,
Antony VB, Abraham E, Thannickal VJ and Liu G: miR-145 regulates
myofibroblast differentiation and lung fibrosis. FASEB J.
27:2382–2391. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu SH, Wu XH, Lu C, Dong L and Chen ZQ:
Lipoxin A4 inhibits proliferation of human lung fibroblasts induced
by connective tissue growth factor. Am J Respir Cell Mol Biol.
34:65–72. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu SH, Wu XH, Lu C, Dong L, Zhou GP and
Chen ZQ: Lipoxin A4 inhibits connective tissue growth
factor-induced production of chemokines in rat mesangial cells.
Kidney Int. 69:248–256. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fierro IM, Kutok JL and Serhan CN: Novel
lipid mediator regulators of endothelial cell proliferation and
migration: Aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). J
Pharmacol Exp Ther. 300:385–392. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Blobe GC, Schiemann WP and Lodish HF: Role
of transforming growth factor beta in human disease. N Engl J Med.
342:1350–1358. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Camoretti-Mercado B and Solway J:
Transforming growth factor-beta1 and disorders of the lung. Cell
Biochem Biophys. 43:131–148. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Samarakoon R, Overstreet JM and Higgins
PJ: TGF-β signaling in tissue fibrosis: Redox controls, target
genes and therapeutic opportunities. Cell Signal. 25:264–268. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dong Z, Zhao X, Tai W, Lei W, Wang Y, Li Z
and Zhang T: IL-27 attenuates the TGF-β1-induced proliferation,
differentiation and collagen synthesis in lung fibroblasts. Life
Sci. 146:24–33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Harris WT, Kelly DR, Zhou Y, Wang D,
MacEwen M, Hagood JS, Clancy JP, Ambalavanan N and Sorscher EJ:
Myofibroblast differentiation and enhanced TGF-B signaling in
cystic fibrosis lung disease. PLoS One. 8:e701962013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tumelty KE, Smith BD, Nugent MA and Layne
MD: Aortic carboxypeptidase-like protein (ACLP) enhances lung
myofibroblast differentiation through transforming growth factor β
receptor-dependent and -independent pathways. J Biol Chem.
289:2526–2536. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee CC, Wang CN, Lee YL, Tsai YR and Liu
JJ: High mobility group box 1 induced human lung myofibroblasts
differentiation and enhanced migration by activation of MMP-9. PLoS
One. 10:e01163932015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Park S, Ahn JY, Lim MJ, Kim MH, Lee SL,
Yun YS, Jeong G and Song JY: IM-412 inhibits transforming growth
factor beta-induced fibroblast differentiation in human lung
fibroblast cells. Biochem Biophys Res Commun. 399:268–273. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chung MJ, Liu T, Ullenbruch M and Phan SH:
Antiapoptotic effect of found in inflammatory zone (FIZZ)1 on mouse
lung fibroblasts. J Pathol. 212:180–187. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hough C, Radu M and Doré JJ: Tgf-beta
induced Erk phosphorylation of smad linker region regulates smad
signaling. PLoS One. 7:e425132012. View Article : Google Scholar : PubMed/NCBI
|
